Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells

Clinical and Experimental Immunology

Volumn 160, Issue 3, 2010, Pages 359-368

  Luo, Y ^a   Han, R ^b   Evanoff, D P ^a   Chen, X ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Tainjin Institute of Urology   (China)

Author keywords

BCG; Bladder cancer; Cytotoxicity; IL 10; Macrophage

Indexed keywords

BCG VACCINE; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; NITRIC OXIDE; RECOMBINANT INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFECT; FEMALE; MACROPHAGE ACTIVATION; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-10; INTERLEUKIN-6; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MICE; MICE, KNOCKOUT; MYCOBACTERIUM BOVIS; NITRIC OXIDE; TUMOR NECROSIS FACTOR-ALPHA; URINARY BLADDER NEOPLASMS;

EID: 77952174579     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04105.x     Document Type: Article

References (58)

1. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol 1980 124 : 38 40.
2. O'Donnell MA, DeWolf WC. Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. New prospects for an old warhorse. Surg Oncol Clin N Am 1995 4 : 189 202.
3. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999 353 : 1689 1694. (Pubitemid 29224536)
4. Patard JJ, Saint F, Velotti F, Abbou CC, Chopin DK. Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review. Urol Res 1998 6 : 155 159. (Pubitemid 28305378)
5. Emoto M, Emoto Y, Buchwalow IB, Kaufmann SH. Induction of IFN-gamma-producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette-Guérin. Eur J Immunol 1999 29 : 650 659. (Pubitemid 29078527)
6. Pryor K, Goddard J, Goldstein D et al. Bacillus Calmette-Guérin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing. Br J Cancer 1995 71 : 801 807.
7. Bohle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990 144 : 53 8. (Pubitemid 20221267)
8. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992 147 : 1636 1642.
9. Peuchmaur M, Benoit G, Vieillefond A et al. Analysis of mucosal bladder leucocyte subpopulations in patients treated with intravesical bacillus Calmette-Guérin. Urol Res 1989 17 : 299 303. (Pubitemid 19228627)
10. Saint F, Patard JJ, Groux Muscatelli B et al. Evaluation of cellular tumor rejection mechanisms in the peritumoral bladder wall after bacillus Calmette-Guérin treatment. Br J Urol Int 2001 88 : 602 610. (Pubitemid 34293806)
11. De Boer EC, de Jong WH, van der Meijden AP et al. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res 1991 19 : 45 50.
12. De Boer EC, De Jong WH, Van Der Meijden AP et al. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin. Cancer Immunol Immunother 1991 33 : 411 416.
13. De Boer EC, De Jong WH, Steerenberg PA et al. Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guérin. In Vivo 1991 5 : 671 677.
14. Bohle A, Nowc C, Ulmer AJ et al. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J Urol 1990 144 : 59 64. (Pubitemid 20221268)
15. Thalmann GN, Sermier A, Rentsch C, Mohrle K, Cecchini MG, Studer UE. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guérin. J Urol 2000 164 : 2129 2133.
16. de Reijke TM, de Boer EC, Kurth KH, Schamhart DH. Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996 155 : 477 482. (Pubitemid 26023528)
17. Saint F, Patard JJ, Maille P et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer. J Urol 2002 167 : 364 367. (Pubitemid 34024586)
18. Nadler R, Luo Y, Zhao W et al. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated anti-tumour activity. Clin Exp Immunol 2003 131 : 206 216. (Pubitemid 36205130)
19. Luo Y, Chen X, O'Donnell MA. Mycobacterium bovis bacillus Calmette-Guerin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol 2007 147 : 370 378. (Pubitemid 46096016)
20. Wang J, Wakeham J, Harkness R, Xing Z. Macrophages are a significant source of type 1 cytokines during mycobacterial infection. J Clin Invest 1999 103 : 1023 1029. (Pubitemid 29169610)
21. Atkinson S, Valadas E, Smith SM, Lukey PT, Dockrell HM. Monocyte-derived macrophage cytokine responses induced by M. bovis BCG. Tuber Lung Dis 2000 80 : 197 207.
22. Calorini L, Bianchini F, Mannini A et al. IFN-gamma and TNF-alpha account for a pro-clonogenic activity secreted by activated murine peritoneal macrophages. Clin Exp Metastasis 2002 19 : 259 264. (Pubitemid 34553526)
23. Baran J, Baj-Krzyworzeka M, Weglarczyk K, Ruggiero I, Zembala M. Modulation of monocyte-tumour cell interactions by Mycobacterium vaccae. Cancer Immunol Immunother 2004 53 : 1127 1134. (Pubitemid 39506402)
24. Luo Y, Yamada H, Chen X et al. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity. Clin Exp Immunol 2004 137 : 24 34. (Pubitemid 38869774)
25. Luo Y, Yamada H, Evanoff DP, Chen X. Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells. Clin Exp Immunol 2006 146 : 181 188. (Pubitemid 44393852)
26. Yamada H, Kuroda E, Matsumoto S, Matsumoto T, Yamada T, Yamashita U. Prostaglandin E2 down-regulates viable bacille Calmette-Guérin-induced macrophage cytotoxicity against murine bladder cancer cell MBT-2 in vitro. Clin Exp Immunol 2002 128 : 52 8. (Pubitemid 34451179)
27. Yamada H, Matsumoto S, Matsumoto T, Yamada T, Yamashita U. Murine IL-2 secreting recombinant bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J Urol 2000 164 : 526 531. (Pubitemid 30481978)
28. Pang AS, Morales A. BCG induced murine peritoneal exudate cells: cytotoxic activity against a syngeneic bladder tumor cell line. J Urol 1982 127 : 1225 1229. (Pubitemid 12088831)
29. Ware CF, VanArsdale S, VanArsdale TL. Apoptosis mediated by the TNF-related cytokine and receptor families. J Cell Biochem 1996 60 : 47 55.
30. Laster SM, Wood JG, Gooding LR. Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol 1988 141 : 2629 2634.
31. Umansky V, Schirrmacher V. Nitric oxide-induced apoptosis in tumor cells. Adv Cancer Res 2001 82 : 107 131. (Pubitemid 32613384)
32. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989 170 : 2081 2095.
33. Mosmann TR, Schumacher JH, Fiorentino DF, Leverah J, Moore KW, Bond MW. Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay. J Immunol 1990 145 : 2938 2945. (Pubitemid 20382564)
34. O'Garra A, Stapleton G, Dhar V et al. Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol 1990 2 : 821 832. (Pubitemid 20307067)
35. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991 174 : 1209 1220.
36. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993 11 : 165 190. (Pubitemid 23115005)
37. Qin Z, Noffz G, Mohaupt M, Blankenstein T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol 1997 159 : 770 776. (Pubitemid 127484228)
38. Richter G, Krüger-Krasagakes S, Hein G, Hüls C, Schmitt E, Diamantstein T, Blankenstein T. Interleukin 10 transfected into Chinese hamster ovary cells prevents tumor growth and macrophage infiltration. Cancer Res 1993 53 : 4134 4137. (Pubitemid 24146753)
39. de Waal Malefyt R, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991 174 : 915 924.
40. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993 151 : 1224 1234. (Pubitemid 23219258)
41. Willems F, Marchant A, Delville JP, Gérard C, Delvaux A, Velu T, de Boer M, Goldman M. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 1994 24 : 1007 1009. (Pubitemid 24093803)
42. Steinbrink K, Wölfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997 159 : 4772 4780. (Pubitemid 127471012)
43. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997 389 : 737 742. (Pubitemid 27458961)
44. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991 147 : 3815 3822.
45. Cenci E, Romani L, Mencacci A, Spaccapelo R, Schiaffella E, Puccetti P, Bistoni F. Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur J Immunol 1993 23 : 1034 1038. (Pubitemid 23120162)
46. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med 1991 174 : 1549 1555.
47. Summerhayes IC, Franks LM. Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst 1997 62 : 1017 1023.
48. Mickey DD, Mickey GH, Murphy WM, Niell HB, Soloway MS. In vitro characterization of four N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) induced mouse bladder tumors. J Urol 1982 127 : 1233 1237.
49. Liu W, O'Donnell MA, Chen X, Han R, Luo Y. Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro. Cancer Immunol Immunother 2009 58 : 1647 1655.
50. Luo Y, Chen X, O'Donnell MA. Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect. Cytokine 2003 21 : 17 26. (Pubitemid 36369372)
51. Hawkyard SJ, Jackson AM, Prescott S, James K, Chisholm GD. The effect of recombinant cytokines on bladder cancer cells in vitro. J Urol 1993 150 : 514 518. (Pubitemid 23215915)
52. Choi SC, Oh HM, Park JS et al. Soluble factor from murine bladder tumor-2 cell elevates nitric oxide production in macrophages and enhances the taxol-mediated macrophage cytotoxicity on tumor cells. Cancer Invest 2003 21 : 708 719.
53. Petricevich VL, Alves RC. Role of cytokines and nitric oxide in the induction of tuberculostatic macrophage functions. Mediat Inflamm 2000 9 : 261 269. (Pubitemid 32096979)
54. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989 56 : 731 740. (Pubitemid 19082507)
55. Hamerman JA, Aderem A. Functional transitions in macrophages during in vivo infection with Mycobacterium bovis bacillus Calmette-Guérin. J Immunol 2001 167 : 2227 2233. (Pubitemid 32747534)
56. Zhao W, Schorey JS, Bong-Mastek M, Ritchey J, Brown EJ, Ratliff TL. Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer 2000 86 : 83 8. (Pubitemid 30133991)
57. Halak BK, Maguire HC Jr., Lattime EC. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 1999 59 : 911 917.
58. Yang AS, Lattime EC. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 2003 63 : 2150 2157.